Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3395-3401

  Tiano, Howard F ^a   Loftin, Charles D ^a   Akunda, Jackie ^a   Lee, Christopher A ^a   Spalding, Judson ^a   Sessoms, Alisha ^a   Dunson, David B ^a   Rogan, Eleanor G ^b   Morham, Scott G ^c   Smart, Robert C ^d   Langenbach, Robert ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c Utah   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BROXURIDINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA ADDUCT; ENZYME DEFICIENCY; EPIDERMIS CELL; FEMALE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN TUMOR;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; CARCINOGENS; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DNA ADDUCTS; FEMALE; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KERATINOCYTES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PAPILLOMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SKIN; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 0037096879     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Prostaglandin endoperoxide H synthases-1 and -2
2. Cyclooxygenases 1 and 2
3. Aspirin use and reduced risk of fatal colon cancer
4. Aspirin and the potential role of prostaglandins in colon cancer
5. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
6. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
7. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
8. The cyclooxy-genase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
9. Celecoxib inhibits N-butyl-N-(4-hydroxy-butyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
10. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
11. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
12. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine
13. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2
14. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
15. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
16. Suppression of intestinal polyposis in Apc(Δ716) knockout mice by inhibition of cyclooxygenase 2 (COX-2)
17. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
18. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
19. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
20. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis
21. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion)
22. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
23. Why there are two cyclooxygenase isozymes
24. Regression models and life tables
25. A modified Jonckheere test against ordered alternatives when ties are present at a single extreme value
26. Identification and quantitation of 7,12-dimethylbenz[a]anthracene-DNA adducts formed in mouse skin
27. Altered regulation of growth and expression of differentiation-associated keratins in benign mouse skin tumors
28. Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13-acetate treatment of mouse skin: An in vivo model for cell cycle regulation
29. Carcinogen substrate specificity of human COX-1 and COX-2
30. Cancer initiation by polycyclic aromatic hydrocarbons results from formation of stable DNA adducts rather than apurinic sites
31. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis
32. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
33. Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis
34. Identification of a major keratinocyte cell envelope protein, Ioricrin
35. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA
36. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin
37. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras
38. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors
39. Failure of programmed cell death and differentiation as causes of tumors: Some simple mathematical models
40. Differentiation: A suitable strategy for cancer chemotherapy?
41. The rise and fall of apoptosis during multistage tumorigenesis: Down-modulation contributes to tumor progression from angiogenic progenitors
42. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis
43. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts